The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy
Open accessAbstract
Recurrent malignancy remains a significant complication after allogeneic hematopoietic cell transplantation (HCT). Efforts to decrease relapse have included donor lymphocyte infusion to stimulate donor anti-recipient T-cell allorecognition of major and minor histocompatibility differences. Recently, alloreactive effects of donor natural killer cell-mediated inhibitory killer immunoglobulin-like receptor (KIR) recognition of recipient HLA-C and -B ligands have been described. We examined KIR ligand effects on risk of relapse in 1770 patients undergoing myeloablative T-replete HCT from HLA-matched or -mismatched unrelated donors for the treatment of myeloid and lymphoid leukemias. KIR ligands defined by HLA-B and -C genotypes were used to determine donor-recipient ligand incompatibility or recipient lack of KIR ligand. Among HLA-mismatched transplantations, recipient homozygosity for HLA-B or -C KIR epitopes predicted lack of KIR ligand and was associated with a decreased hazard of relapse (hazard ratio, 0.61; 95% confidence interval, .043-0.85; P = .004). Absence of HLA-C group 2 or HLA-Bw4 KIR ligands was associated with lower hazards of relapse (hazard ratio, 0.47; 95% confidence interval, 0.28-0.79, P = .004; hazard ratio, 0.56; 95% confidence interval, 0.33-0.97; P = .04, respectively). The decrease in hazard of relapse in patients with acute myelogenous leukemia was similar to that in patients with chronic myelogenous leukemia and acute lymphoblastic leukemia (P = .95). Recipient homozygosity for HLA-B or -C epitopes that define KIR ligands is likely to be a predictive factor for leukemia relapse after myeloablative HCT from HLA-mismatched unrelated donors. This effect was not observed in HLA-identical unrelated transplants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Cited by
Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038687 · Cited by 616
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
Self-citationKasamon, Y. L., Luznik, L., Leffell, M. S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., Morris, L. E., Crilley, P. A., O'Donnell, P. V., Rossiter, N., et al. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.011 · Cited by 281
Metadata
- Authors
- Hsu, K. C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.-D., Bornhäuser, M., Christiansen, F., Gratwohl, A., Morishima, Y., Oudshoorn, M., Ringden, O., van Rood, J. J., & Petersdorf, E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2006-08
- Volume
- 12
- Issue
- 8
- Pages
- 828-836
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2171160333
- Cited by
- 212
- References
- 1
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. https://app.cochat.ai/papers/10.1016/j.bbmt.2006.04.008
- The paper
- Hsu, K. C., Gooley, T., Malkki, M., Pinto-Agnello, C., Dupont, B., Bignon, J.-D., Bornhäuser, M., Christiansen, F., Gratwohl, A., Morishima, Y., Oudshoorn, M., Ringden, O., van Rood, J. J., & Petersdorf, E. (2006). KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2006.04.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.